Trastuzumab biosimilar (Dong-A ST/Meiji Seika Pharma)

曲妥珠单抗生物类似药 (Dong-A ST/Meiji Seika Pharma)

Report date: 2025/05/29 15:40:03

Base Information

Drug NameTrastuzumab biosimilar (Dong-A ST/Meiji Seika Pharma)
Drug Alias NameDA-3111DMB-3111
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeL01XC03
Related LinksN/A